Iambic Therapeutics, Inc.: Citigroup initiates coverage with buy rating; price target $22
IAM•Citigroup initiated coverage of Iambic Therapeutics with a buy rating and a $22 price target.
Related News
Portillo's Inc: UBS raises target price to $7 from $4.5
PTLO•
CPI Aerostructures publishes update to financial calendar
CVU•
Constellation gains after Q3 profit beat, 2026 forecast raise
CEG•
BioLargo leads PFAS masterclass at International Water Conference
BLGO•
Vireo Growth completes acquisition of FLUENT
VREOF•